Open AccessP‐090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
Author(s) -
F. GALACTÉROS,
E. VOSKARIDOU,
A. HABIBI,
G. CANNAS,
L. JOSEPH,
G. LOKO,
M. DE MONTALEMBERT
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000873248.60171.71
Subject(s) - medicine , hydroxycarbamide , cohort , disease , clinical trial , population , clinical research , pediatrics , prospective cohort study , environmental health